Vacinas
A batalha para fabricar vacinas contra COVID em países de baixa renda.
27 Set, 2021 | 11:33hThe fight to manufacture COVID vaccines in lower-income countries – Nature
[Comunicado de imprensa – ainda não publicado] Pfizer anuncia que sua vacina contra COVID-19 produz forte resposta imune em crianças de 5 a 11 anos.
27 Set, 2021 | 11:00hComentários:
Pfizer says COVID-19 vaccine safe, effective in younger children – CIDRAP
Comentários no Twitter
I'm so glad to see that Pfizer has data to submit for their vaccine for 5-11 year olds. But any strong assertions about safety, such as for low incidence side-effects like myocarditis, cannot made from a trial of ~1500 children.
— Eric Topol (@EricTopol) September 20, 2021
(fio – clique para saber mais)
BREAKING NEWS: Pfizer releases results of 5-11 year old trial for its vaccine. 2-dose 10 microgram regimen (Pfizer uses 30 mcg for 12 and up) administered 21 days apart (sigh, we now know we need longer duration between doses for better effectiveness)https://t.co/43MHnlZgqg
— Monica Gandhi MD, MPH (@MonicaGandhi9) September 20, 2021
(fio – clique para saber mais)
BNT-Pfizer vax trial readout (press release) for kids 5-11: it's 2 doses of 10 µg dose – a third of the size of that for 12+. They conclude it had similar results to full dose vax for the 16-25 year age group: minimal data in press release…1/3https://t.co/MgYCmWYhO2
— Hilda Bastian, PhD (@hildabast) September 20, 2021
Desatrelando a vacinação da política: um chamado para a ação.
27 Set, 2021 | 10:57hUncoupling vaccination from politics: a call to action – The Lancet
Relatório do CDC | Vacina da Moderna está associada a alta efetividade (93%) contra hospitalização por Covid-19 em comparação às vacinas da Pfizer (88%) e da J&J (71%).
20 Set, 2021 | 13:59hComentários:
CDC: Moderna COVID vaccine most protective against hospital cases – CIDRAP
CDC data: Moderna vaccine has edge in preventing COVID-19 hospitalizations – UPI
Comentário no Twitter
Turns out all vaccines are not equal! https://t.co/yP6eC6o78i via @CDCgov Among adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization (Mar 11–Aug 15, 21) was ⬆️for @moderna_tx (93%) than @pfizer (88%) and @JNJNews vaccine (71%).
— Carlos del Rio (@CarlosdelRio7) September 17, 2021
Um painel da FDA afirma que somente americanos de alto risco e os maiores de 65 anos deveriam tomar as doses de reforço contra Covid.
20 Set, 2021 | 13:56hAn FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters – NPR
Ver também:
5 reasons why FDA advisers did not recommend Covid-19 booster shots for everyone – CNN
Top doctors say not so fast to Biden’s boosters-for-all plan – Associated Press
Conteúdos relacionados:
Third shot: UK to offer COVID booster jabs to over 50s.
COVID-19 vaccine efficacy does not support boosters for general population, review concludes.
COVID vaccine effects wane over time but still prevent death and severe illness.
What’s the evidence for COVID-19 booster shots?
Opinião | Vacinar o mundo antes de começar as doses de reforço contra COVID – “Menos de 0,5% das doses de vacina foram distribuídas a pessoas de países de baixa renda.”
20 Set, 2021 | 13:53hVaccinate the World before Starting COVID Booster Shots – Scientific American
Conteúdo relacionado: WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.
Série de casos | Trombocitopenia induzida por vacina com cefaleia grave pode preceder uma trombose sinusal venosa cerebral em vários dias – Pacientes com cefaleia grave 5 a 20 dias depois de tomarem vacina com vetor de adenovírus contra Covid-19 devem relizar teste para trombocitopenia e níveis de D-dímero e, se disponível, teste para anticorpo anti-PF4-heparina IgG.
17 Set, 2021 | 12:44hVaccine-Induced Thrombocytopenia with Severe Headache – New England Journal of Medicine
Comentário no Twitter
Experience with 11 patients suggests that elements of VITT (severe headache, elevated d-dimer levels, and positivity for anti-PF4 antibodies) after ChAdOx1 nCoV-19 vaccination may precede VITT. #Covid19Vaccines #COVID19 #SARSCoV2 #IDTwitter https://t.co/mzBgjJIE6l pic.twitter.com/wGqb1gKFXk
— NEJM (@NEJM) September 15, 2021
Estudo observacional em Israel sugere proteção adicional da terceira dose da vacina da Pfizer em pessoas com mais de 60 anos de idade.
17 Set, 2021 | 12:42hProtection of BNT162b2 Vaccine Booster against Covid-19 in Israel – New England Journal of Medicine
Terceira dose: Reino Unido oferece doses de reforço da vacina contra COVID para maiores de 50 anos de idade.
17 Set, 2021 | 12:40hThird shot: UK to offer COVID booster jabs to over 50s – Associated Press
Efeitos da vacina contra COVID diminuem ao longo do tempo, mas continuam prevenindo morte e doença grave.
17 Set, 2021 | 12:39hCOVID vaccine effects wane over time but still prevent death and severe illness – The Conversation
Conteúdos relacionados:
Perspective | What we actually know about waning immunity.
Another study shows Pfizer mRNA vaccine immunity is reduced over time.
Studies: COVID vaccine protection waning against infection but not hospitalization.
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.


